Skip to content
Medical Health Aged Care

Lighten the overload of Australia’s most common genetic disorder

Haemochromatosis Australia 2 mins read

MEDIA RELEASE

Optus Stadium and 100 other well-known buildings and landmarks across WA and Australia will turn red from tonight until 7 June, shining a light on an extremely common genetic condition that most people have never heard of.

It is part of a worldwide initiative to raise awareness of haemochromatosis – also known as iron overload – and to prompt people to get tested. Most people know that having too little iron in your body can cause anaemia, which is characterised by tiredness and lethargy, but few people know that the same symptoms can also be caused by having too much iron.

The hereditary condition, which is passed on from both biological parents, is simple to detect and treat but if undiagnosed or ignored can lead to serious and life-threatening illness, including liver disease and diabetes. One in seven Australians carry one copy of the defective gene, while and one in 200 Australians have two copies, which puts them at high risk of developing the condition.

Dr Dan Johnstone, an iron researcher who also has the condition, says early detection is key to minimising or preventing permanent damage. “Awareness of haemochromatosis is more important now than ever as early diagnosis will help save lives, cut health costs and reduce unnecessary suffering for so many individuals and families. Everybody is different; some people will have early symptoms of fatigue or joint aches while others won’t know they have the condition until the damage is already done. Anyone who suspects they may have this condition should ask their GP for a blood test. Haemochromatosis is not a burden in your life if you get on to it early. Early diagnosis is key to managing and reducing complications. It is usually managed by a regime of therapeutic blood donations, at an Australian Red Cross Lifeblood donor centre. This is a classic win-win situation, benefiting both the individual and the community,” said Dr Johnstone.

Haemochromatosis Australia spokesperson, Tony Moorhead, said, “Despite being the most common genetic disorder in Australia, haemochromatosis is often underdiagnosed because people don’t know about it and symptoms are non-specific. Unfortunately, most of those affected aren’t diagnosed until aged in their mid-forties and already suffering ill health. “There are people with the condition who should have been diagnosed decades earlier. This would have reduced the suffering, medical cost and even loss of life that results from iron overload. If haemochromatosis is detected early enough it is completely preventable – those affected need never get sick, they simply need to donate blood to maintain normal iron levels and their health.” Mr Moorhead says. “Hereditary haemochromatosis is estimated to cost Australia’s health system about $280 million annually and to add further cost burdens by compounding other chronic conditions.” Haemochromatosis is easy to test, simple to treat but tragic to ignore. -

 

ENDS Landmarks lighting up can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/


Key Facts:

* Australia's most common genetic disorder, that most have never heard of

* World Haemochromatosis Awareness Week June 1 - 7 

*Interviews available 

* Landmarks lighting up in red can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/


About us:

To find out more visit www.ha.org.au/haemochromatosis


Contact details:

Kellie Curtain M: 0412339690 [email protected] 

Media

More from this category

  • Medical Health Aged Care
  • 10/03/2026
  • 16:28
Phebra

Phebra launches Rapiblyk® in Australian healthcare settings

Australian Pharmaceutical company Phebra (‘Company’) has announced the launch of Rapiblyk® (landiolol hydrochloride), an ultra‑short‑acting, cardio-selective receptor antagonist, indicated for rapid control of ventricular rate in patients with severe, acute cardiac arrhythmias (irregular rapid heart rate) in critical care settings. Clinical studies have demonstrated that Rapiblyk® enables safe, effective heart rate control with limited impact on blood pressure and inotropy (heart contractility). Rapiblyk® has a very short half life delivering a fast onset and offset of action. This provides clinicians with a higher level of precision in life-threatening situations. Phebra CEO Andre Vlok highlighted how Rapiblyk® strengthens the company's critical…

  • Medical Health Aged Care
  • 10/03/2026
  • 16:09
Dementia Australia

On this weekend – Memory Walk & Jog Adelaide!

The 2026 Adelaide Memory Walk & Jog is fast approaching, with the much-anticipated event taking place this weekend on Sunday 15 March at Wigley Reserve, Glenelg. With the big day kicking off at 7:30am, we welcome everyone in the Adelaide community to join their fellow participants as they walk, jog or run for better brain health and to help raise money in support of people living with dementia, their families and carers.Join MC Mark Gibson for a wonderful fun, family friendly day out. More than 960 people have already signed-up to take part – but there’s always room for more…

  • Contains:
  • Medical Health Aged Care
  • 10/03/2026
  • 16:01
Dementia Australia

Memory Walk & Jog Illawarra just weeks away!

The 2026 Illawarra Memory Walk & Jog is only a few short weeks away, with the event taking place on Sunday 22 March at Lang Park. Memory Walk & Jog returns to Illawarra in 2026, bringing the community together to get active for brain health and to show support for people impacted by dementia. Illawarra Memory Walk & Jog is a key Dementia Australia community event, helping raise funds to deliver invaluable support, education and resources for people living with dementia, their families and carers. Memory Walk & Jog is about being part of the community and feeling supported. Participants…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.